COMP <GO>
TECH vs LLY // EV/EBITDA & P/E VALUATION
Bio-Techne Corp (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: TECH 2
— LLY 13
▲ EV/EBITDA & P/E VALUATION LEADER: LLY
LAST: $72.66 (-0.07%) • MKT CAP: $11.40B
valuation
91.3x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 83.64% | -18.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 32.36% | -28.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 91.3x | 36.4x | +54.88 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 2.30% | -0.05 | LLY | /fcf-yield <GO> |
| Operating Margin | 8.40% | 40.21% | -31.81 | LLY | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 31.90% | -25.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 45.51% | -40.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.49% | -0.05 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.12 | 9.29 | -2.17 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | TECH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 77.9 | -20.68 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.51 | +0.37 | TECH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 26.3x | +113.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.40B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | LLY REV | TECH GROSS % | LLY GROSS % | TECH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $65.18B | 64.8% | 83.0% | $256.6M | $16.81B |
| FY 2024 | $1.16B | $45.04B | 66.4% | 81.3% | $236.1M | $8.82B |
| FY 2023 | $1.14B | $34.12B | 44.0% | 79.3% | $203.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
LLY // BETA 0.51